PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Genexine Life Science is simultaneously pursuing balance-sheet repair and pipeline restart while navigating capital impairment, a production halt at its US subsidiary VGXI, and repeated changes in its largest shareholder.
Revenue fell for four straight years from KRW 48.7bn (2022) to KRW 23.0bn (2025), with operating losses exceeding KRW 40bn every year.
The company was designated an administrative issue due to an expanding capital impairment ratio, and has pursued a 5-to-1 reverse stock split followed by third-party capital increases.
Core subsidiary VGXI, a Texas-based plasmid DNA CDMO, halted production amid legal disputes, triggering a listing-eligibility review by the exchange.
Governance uncertainty persists as the largest shareholder changed to Dongban Sungjang Investment Association in August 2025 and then to Revolt Investment Association in August 2026.
The company has flagged renewed pursuit of an IND approval for SFTS vaccine candidate GLS-5140 within 2026 as a new R&D catalyst.
Founded in 1976 and listed on the KOSPI in 1987, Genexine Life Science originally operated an interlining and processed-fabric business (Interlon, Fabron) before launching a biopharmaceutical drug-development business in earnest from late 2005.
Its core platform is DNA vaccine technology; COVID-19 vaccine candidate GLS-5310 is a plasmid-based DNA vaccine encoding the Spike and Viroporin proteins.
Oral small-molecule immune modulator GLS-1027 (international name zenuzolac) has been pursued not only to prevent COVID-19 severity but also for expanded indications including long COVID and non-infectious uveitis.
More recently, the company has pushed to resume clinical development of SFTS (severe fever with thrombocytopenia syndrome) vaccine candidate GLS-5140, with related preclinical data published in the journal Nature Communications.
The revenue backbone is wholly owned Texas-based subsidiary VGXI, a contract development and manufacturing organization (CDMO) producing plasmid DNA used in gene therapies, DNA vaccines, and RNA medicines. VGXI has weighed on group results for years due to heavy capital investment and chronic losses.
In the plasmid DNA CDMO market, a small number of specialized players hold an oligopolistic position; the company has stated VGXI passed a US FDA GMP regulatory inspection in May 2025, validating capability to support customer biologics license applications.
However, subsequent liquidity deterioration led to a temporary production halt at the Texas plant along with wage-payment disputes and litigation, destabilizing the CDMO revenue base itself.
The company today rests on three pillars—legacy fabric business, DNA vaccine/immune-modulator drug pipeline, and VGXI CDMO—but normalizing CDMO operations and repairing the balance sheet have become management's top priorities.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩6.8B | -₩10.2B | −149.5% |
| 2025Q3 | ₩5.1B | -₩11.7B | −229.7% |
| 2025Q4 | ₩2.7B | -₩13.1B | −494.9% |
| 2026Q1 | ₩2.6B | -₩2.3B | −90.8% |
| 2026Q2 | ₩2.1B | -₩12.8B | −623.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩48.7B | -₩40.1B | -₩38.1B | −82.3% | −21.0% | 22.8% |
| 2023 | ₩40.2B | -₩48.4B | -₩77.8B | −120.3% | −69.8% | 35.4% |
| 2024 | ₩35.7B | -₩43B | -₩48.5B | −120.5% | −56.7% | 76.8% |
| 2025 | ₩23B | -₩44B | -₩51.9B | −191.1% | −126.8% | 191.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue declined for four straight years, from KRW 48.72bn in 2022 to KRW 40.20bn (2023), KRW 35.72bn (2024), and KRW 23.04bn (2025).
Over the same period operating losses stayed above KRW 40bn every year: -KRW 40.08bn (2022), -KRW 48.37bn (2023), -KRW 43.04bn (2024), and -KRW 44.04bn (2025), while the operating margin deteriorated from -82.3% to -191.1%, showing revenue shrank far faster than fixed costs could be cut.
Net loss attributable to owners swung from -KRW 38.06bn (2022) to -KRW 77.77bn (2023), then narrowed to -KRW 48.54bn (2024) and widened again to -KRW 51.85bn (2025)—large losses persisted despite year-to-year volatility.
Equity fell sharply each year, from KRW 181.47bn (2022) to KRW 111.49bn (2023), KRW 85.61bn (2024), and KRW 40.90bn (2025), reflecting rapid capital impairment, while the debt ratio jumped from 22.8% to 35.4%, 76.8%, and 191.5%.
Operating cash flow was consistently negative, ranging roughly -KRW 16bn to -KRW 24bn annually, underscoring continuous cash burn absent external funding.
Quarterly revenue kept contracting—from KRW 6.81bn (2025Q2) to KRW 5.08bn (Q3), KRW 2.65bn (Q4), KRW 2.58bn (2026Q1), and KRW 2.06bn (2026Q2)—tracking the period of VGXI's Texas plant production disruption.
Operating losses briefly narrowed to -KRW 2.34bn in 2026Q1 before widening again to -KRW 12.81bn in 2026Q2, showing significant volatility.
Summing the most recent four quarters (2025Q3 through 2026Q2), the owners' net loss totaled roughly KRW 48.9bn, indicating the annualized loss run-rate has not meaningfully narrowed.
Korea's biopharmaceutical sector is undergoing a restructuring phase in 2026, marked by a sharp rise in the number of small-cap listed companies designated as administrative issues or facing delisting due to accumulated financial distress.
Cases of companies undergoing listing-eligibility reviews over capital impairment or audit-opinion issues, similar to Genexine Life Science's situation, have increased, prompting some observers to characterize the broader market as being in a phase of weeding out marginal firms.
The plasmid DNA CDMO market has a long-term growth backdrop driven by expanding pipelines of gene therapies, mRNA, and DNA vaccines, but competition for manufacturing contracts is intense, and it typically takes considerable time for new or smaller CDMO players to secure stable revenue.
VGXI passed an FDA GMP regulatory inspection, validating some technical capability, but is now classified as a case that has stumbled on the harder task of securing and sustaining actual manufacturing orders and revenue.
Several other domestic pharma/bio companies that entered the CDMO business have likewise failed to generate meaningful order wins for years, illustrating the intensity of competition and barriers to entry in this segment.
In the infectious-disease vaccine field, government support for public vaccine development against high-risk emerging and re-emerging diseases without commercialized preventive vaccines—such as SFTS—continues, and alignment with such policy is a variable that could influence the commercialization path of individual pipeline assets.
The company has stated a plan targeting 2026 for finalizing outstanding IND requirements, conducting additional nonclinical studies, holding pre-IND meetings with Korea's Ministry of Food and Drug Safety, submitting the IND, and obtaining Phase 1/2a approval for SFTS vaccine candidate GLS-5140.
Management has also said it is exploring cooperation with government bodies such as the Korea Disease Control and Prevention Agency to develop GLS-5140 into a public vaccine.
On the balance-sheet front, trading was halted from June 25, 2026 for a listing change tied to a 5-to-1 reverse stock split, and the halt was later extended after reports emerged of a production and sales halt at CDMO subsidiary VGXI, triggering an exchange review of whether the case warrants a listing-eligibility deliberation.
Ahead of that review outcome, the board resolved on August 4, 2026 to raise KRW 15.0bn through a third-party allotment; once payment is completed, newly formed Revolt Investment Association is set to become the largest shareholder with a 25.51% stake.
Proceeds were earmarked for a KRW 7.0bn loan to fund VGXI's plant operating costs, KRW 6.1bn for head-office operating expenses, and KRW 1.9bn for debt repayment.
Regarding VGXI, a loan repayment to US-based C2R matures September 1 and a Sangsangin Savings Bank loan matures September 23, leaving near-term funding and repayment execution as key variables.
The company has stated that the transfer of legal title to VGXI's Texas plant to a financial institution is a collateralized loan-type transaction under which it retains a repurchase right, and does not constitute a true sale.
Over the past four years, continuous revenue decline combined with large operating and net losses has rapidly eroded shareholders' equity, expanding the company's capital impairment ratio.
Given this financial trajectory, it is useful to weigh the current trading level against net asset value, assessed relative to the multi-year band rather than a single point in time. Dividends have not been paid in recent fiscal years, making dividend-based valuation comparisons difficult to apply here.
On the earnings side, loss magnitude has fluctuated year to year without a clear sign of profit recovery so far, a variable the market continues to watch alongside the ongoing capital restructuring (reverse split and capital increases).
Interpreting valuation here also requires factoring in the special situation of repeated attempts to resolve capital impairment and an ownership structure still in flux.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
GLS-5140 targets SFTS, a disease with no commercialized preventive vaccine, and already has preclinical data published in an international journal. The company has outlined a strategy to pursue a public-vaccine model in cooperation with government agencies such as the KDCA. If successful, this could secure demand through public procurement without direct private-market competition.
The company has stated VGXI passed an FDA GMP regulatory inspection in May 2025, validating its capability to support biologics license applications, and it holds over two decades of plasmid DNA manufacturing experience.
If production is normalized, there is room for order recovery as gene therapy and nucleic acid medicine pipelines expand industry-wide.
The company is attempting to address capital impairment and secure short-term liquidity simultaneously through a 5-to-1 reverse split and a third-party capital increase. The KRW 15.0bn in proceeds has been earmarked for VGXI plant operating costs and debt repayment. Completion of the new largest-shareholder transition could serve as a catalyst for governance stabilization.
Revenue has declined for four consecutive years since 2022, falling to around KRW 23.0bn in 2025, and quarterly revenue kept shrinking into 2026. If the production halt at core revenue driver VGXI is prolonged, the revenue base itself risks further deterioration. Amid intense CDMO order competition, rebuilding customer trust could take considerable time.
Equity fell from KRW 181.5bn in 2022 to KRW 40.9bn in 2025, less than a quarter in four years, while the debt ratio surged from 22.8% to 191.5%. Repeated reverse splits and capital increases to address impairment have compounded dilution for existing shareholders, and further capital raises cannot be ruled out.
The largest shareholder has changed multiple times within a short period since August 2025, and a delayed disclosure of an ownership change resulted in a formal designation as an unfaithful-disclosure entity along with penalty points.
Because a newly formed investment association is set to become the largest shareholder through a capital increase, uncertainty remains over future management stability, and reports have noted former management retaining substantive decision-making authority over the subsidiary and new business unit.
The company was designated an administrative issue due to an expanding capital impairment ratio, and the exchange conducted a review of whether VGXI's production and sales halt warranted a listing-eligibility deliberation.
Accumulated penalty points from being designated an unfaithful-disclosure entity add further risk of triggering review requirements, and the outcome could result in extended trading halts or additional procedures.
Loans tied to VGXI in the US and to a domestic savings bank have near-term maturities, creating significant short-term repayment pressure. Operating cash flow has posted net outflows every year, reflecting heavy reliance on external funding. Any delay or shortfall in planned fundraising could lead to further financial deterioration.
Key pipeline assets including GLS-5140 and GLS-1027 remain at early-to-mid clinical stages, leaving both success and commercialization timing uncertain. Clinical development requires substantial funding, and whether sustained R&D investment can continue given the current financial condition remains a key question.
The public-vaccine strategy pursued through government cooperation is also still at an early stage, without a concrete contract or approval yet secured.
Check whether the KRW 1.9bn Sangsangin Savings Bank loan is repaid at maturity; any delay in the planned capital-increase payment could disrupt repayment execution.
Confirm whether payment for the KRW 15.0bn third-party capital increase to Revolt Investment Association is completed and the largest-shareholder change is finalized.
Continue monitoring whether VGXI's CDMO production resumes and track follow-up procedures and exchange disclosures related to the listing-eligibility review.
Check the progress of the IND submission and approval process for SFTS vaccine GLS-5140 with Korea's MFDS; achieving the stated target would mark the first milestone toward new clinical entry.
Review the Q3 2026 earnings disclosure to determine whether the revenue and loss trend continues and whether any VGXI production resumption is reflected in revenue.
Genexine Life Science is restructuring its balance sheet through a 5-to-1 reverse split and third-party capital increases amid financial pressure from four consecutive years of revenue decline, large operating and net losses, and rapid capital impairment.
At the same time, business and governance risks have compounded, including a production halt and litigation at core revenue source VGXI, repeated changes in the largest shareholder, and designation as an unfaithful-disclosure entity.
That said, business-level momentum has also been presented, including renewed pursuit of clinical development for SFTS vaccine GLS-5140 and VGXI's FDA GMP validation, and the key watch points going forward are whether completion of the capital increase and normalization of VGXI production translate into actual revenue and cash-flow improvement.
The outcome of the listing-eligibility review and execution on imminent debt maturities are also near-term variables to watch.
Overall, the company faces the dual task of resolving structural crises while attempting a comeback through new pipeline assets, and its path forward could diverge significantly depending on how each of these events unfolds.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.